Epigenomics AG

EANS-News: Epigenomics AG
Epigenomics AG to Provide an Update on the Septin9 Program During a Corporate Workshop on Colorectal Cancer Screening at the Association of Molecular Pathology (AMP) 2012 Annual Meeting


--------------------------------------------------------------------------------
  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------
Company Information/molecular diagnostics


Berlin, Germany, and Seattle, WA, U.S.A. (euro adhoc) - Press release

Epigenomics AG to Provide an Update on the Septin9 Program During a Corporate
Workshop on Colorectal Cancer Screening at the Association of Molecular
Pathology (AMP) 2012 Annual Meeting 

* Partners Quest Diagnostics and ARUP Laboratories to discuss experiences with
laboratory developed test versions using the methylated Septin9 DNA biomarker

Berlin, Germany, and Seattle, WA, U.S.A., October 22, 2012 - Epigenomics AG
(Frankfurt Prime Standard: ECX), the cancer molecular diagnostics company, today
announced that it will host a corporate workshop at the Association of Molecular
Pathology (AMP) 2012 Annual Meeting.  Attendees of AMP, analysts, investors and
media representatives are cordially invited to join this event on October 24,
2012 at 4pm PST in room 102 at the Long Beach Convention & Entertainment Center
in Long Beach, CA.

The workshop will include a presentation of the results from the pivotal trial
with Epigenomics' colorectal cancer blood test, Epi proColon®, for US pre-market
approval, as well as discussions on the individual experiences and perspectives
of various groups using the Septin9 biomarker. Presentations will be made by:

* Nicholas Potter, Ph.D., FACMG, Chief Scientific Officer and Director of
Molecular Diagnostics at Molecular Pathology Laboratory Network, Inc.,
Maryville, TN

 "Septin9 in the Molecular Diagnostics Setting: Results of the Epigenomics
Pivotal Trial"

* Frederic Waldman, MD Ph.D., Medical Director, Cancer Diagnostics, Quest
Diagnostics Nichols Institute, San Juan Capistrano CA

"ColoVantage®, Methylated Septin9: Quest Diagnostics' Experience with its
Laboratory-Developed Blood Test for the Colorectal Cancer Genetic Marker After
Tens of Thousands of Tests Performed"

* Karen Heichman, Ph.D., Adjunct Associate Professor of Pathology at the
University of Utah School of Medicine and VP Oncology Technology Development and
Licensing of ARUP Laboratories, Inc., Salt Lake City, UT

 "ARUP's Experience with the SEPT9 Blood-based Colorectal Cancer Test" 

* Professor Dr. Béla Molnár, MD Ph.D., Department of Internal Medicine of
Semmelweis University in Budapest, Hungary

 "Update on Septin9 Research" 

Karen Heichman, Ph.D., Adjunct Associate Professor of Pathology at the
University of Utah School of Medicine and VP Oncology Technology Development and
Licensing of ARUP said: "ARUP continues to see steady volumes of our Septin9
colorectal cancer test. Based on our collaborative research demonstrating strong
patient preference for blood-based testing, it is clear that as physicians and
patients become informed, molecular tests such as Septin9 will play an
increasing role in patient care."

"We are extremely pleased to have this year's lineup of speakers and
contributors at our workshop," said Noel Doheny, CEO of Epigenomics' US
Subsidiary. "AMP represents an important opportunity to inform the medical
community of the work that we and our partners are doing using Septin9 testing."


Dr. Thomas Taapken, CEO/CFO of Epigenomics AG remarked that "Epigenomics is
highly anticipating the results of its Septin9 biomarker-based test, Epi
proColon®, compared directly to the fecal immunochemical test (FIT). The results
of the comparison study will be included in the pre-market application for the
use of Epi proColon® as a colorectal cancer screening test to be submitted to
FDA later this year."

The workshop is designed to update the AMP laboratory community about the
growing opportunity for laboratories to help improve participation in colorectal
cancer testing. The increasing availability of blood-based molecular diagnostic
method allows patients more flexible choices for their routine health care. The
addition of these types of assays provides an innovative role for molecular
laboratories and builds on their historic molecular testing expertise.  

- Ends -


Contact Epigenomics AG

Antje Zeise
Manager IR | PR 
Epigenomics AG 
Tel +49 (0) 30 24345 368 
ir@epigenomics.com 
www.epigenomics.com

About Epigenomics

Epigenomics (www.epigenomics.com) is a molecular diagnostics company developing
and commercializing a pipeline of proprietary products for cancer. The Company's
products enable doctors to diagnose cancer earlier and more accurately, leading
to improved outcomes for patients. Epigenomics' lead product, Epi proColon®, is
a blood-based test for the early detection of colorectal cancer, which is
currently marketed in Europe and is in development for the U.S.A. The Company's
technology and products have been validated through multiple partnerships with
leading global diagnostic companies including Abbott, QIAGEN, Sysmex, and Quest
Diagnostics. Epigenomics is an international company with operations in Europe
and the U.S.A.

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements involve
certain known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or achievements of
Epigenomics AG to be materially different from any future results, performance
or achievements expressed or implied by such forward-looking statements.
Epigenomics AG is providing this communication as of this date and does not
undertake to update any forward-looking statements contained herein as a result
of new information, future events or otherwise. 

The information contained in this communication does not constitute nor imply an
offer to sell or transfer any product, and no product based on this technology
is currently available for sale by Epigenomics in the United States or Canada.
The analytical and clinical performance characteristics of any Epigenomics
product based on this technology which may be sold at some future time in the
U.S. have not been established.


Further inquiry note:
Antje Zeise | CIRO 
Manager IR/PR 
Epigenomics AG
Tel: +49 30 24345 386

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


company:     Epigenomics AG
             Kleine Präsidentenstraße 1
             D-10178 Berlin
phone:       +49 30 24345-0
FAX:         +49 30 24345-555
mail:     ir@epigenomics.com
WWW:      http://www.epigenomics.com
sector:      Biotechnology
ISIN:        DE000A1K0516
indexes:     Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
             regulated dealing/prime standard: Frankfurt 
language:   English
 

 

 



Das könnte Sie auch interessieren: